Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
17.23
-0.32 (-1.82%)
At close: Jun 26, 2026, 4:00 PM EDT
17.27
+0.04 (0.23%)
After-hours: Jun 26, 2026, 7:56 PM EDT
Company Description
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.
The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases.
The company was founded in 1993 and is headquartered in Edmonton, Canada.
Aurinia Pharmaceuticals Inc.
| Country | Canada |
| Founded | 1993 |
| IPO Date | Jan 26, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 128 |
| CEO | Kevin Tang |
Contact Details
Address: #140, 14315 – 118 Avenue Edmonton, AB T5L 4S6 Canada | |
| Phone | 250 744 2487 |
| Website | auriniapharma.com |
Stock Details
| Ticker Symbol | AUPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001600620 |
| CUSIP Number | 05156V102 |
| ISIN Number | CA05156V1022 |
| Employer ID | 98-1231763 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kevin C. Tang | Chairman and Chief Executive Officer |
| Stephen P. Robertson | Chief Legal Officer, Corporate Secretary and Chief Compliance Officer |
| Peter S. Greenleaf M.B.A. | Consultant |
| Michael S. Hearne CPA | Chief Financial Officer |
| Ryan Cole | Chief Operating Officer |
| Thomas Wei | Chief Scientific Officer |
| Stewart M. Kroll | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 5, 2026 | 144 | Filing |
| Jun 4, 2026 | SCHEDULE 13D/A | Filing |
| Jun 4, 2026 | 8-K | Current Report |
| Jun 4, 2026 | 144 | Filing |
| Jun 2, 2026 | 144 | Filing |
| May 11, 2026 | 144 | Filing |
| May 11, 2026 | 144 | Filing |
| May 11, 2026 | 144 | Filing |
| May 11, 2026 | 8-K | Current Report |
| May 7, 2026 | 10-Q | Quarterly Report |